Omeros Logo     Print Page  |  Close Window

2018 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
02/15/18Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Greater than 16-Fold Improvement in Survival Compared to Historical Control -- SEATTLE--(BUSINESS WIRE)--Feb. 15, 2018-- Omeros Corporation (NASDAQ: OMER) today announced new results from the company’s ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). The data demonstrate an increase in median overall survival in HCT-TMA patients treated with OMS721 c... 
 Printer Friendly Version
01/22/18European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy
-- EMA also reviewing Priority Medicines application for the drug in IgAN -- SEATTLE--(BUSINESS WIRE)--Jan. 22, 2018-- Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Omeros’ application for orphan drug designation of OMS721 in the treatment of primary Immunoglobulin A nephropathy (IgAN). OMS721 is Omeros’ lead human monoc... 
 Printer Friendly Version
01/03/18Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
-- Also Initiates OMS721 Phase 3 Program in HCT-TMA -- SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration (FDA) on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy (IgAN). Patient enrollment is expected to begin early next month. The single Phase 3 trial is a randomized, double... 
 Printer Friendly Version